Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PLx Pharma has successfully completed a clinical trial of PL 2100, also known as Aspirin-PC and demonstrated its bioequivalence with regular aspirin.
Subscribe to our email newsletter
This trial demonstrates PL 2100 Aspirin-PC may bridge to the safety and efficacy of aspirin for prescription (Rx) treatment and prevention of secondary prevention of stroke and myocardial infarction and over-the-counter analgesic and fever indications.
According to the company, this trial is a first step in a clinical development program that will investigate PL 2100 Aspirin-PC as an aspirin formulation that is potentially safer for the gastrointestinal (GI) tract. Unlike other approaches to GI safety, such as enteric coated aspirin products which markedly delay the anti-platelet effects, PL 2100 is being investigated for rapid anti-platelet, analgesic and anti-pyretic efficacy with potentially improved gastrointestinal safety.
Byron Cryer, managing director of University of Texas Southwestern Medical School, said: “A GI safer aspirin product that provides rapid anti-platelet activity with pharmacokinetics and pharmacodynamics identical to regular aspirin would be a welcome addition for the safer treatment of cardiovascular diseases and pain.”